Literature DB >> 11155292

Relation between the insertion/deletion polymorphism of the angiotensin I converting enzyme gene and restenosis after coronary stenting.

A Gürlek1, S Güleç, H Karabulut, I Bokesoy, E Tutar, G Pamir, A Alpman, R Toydemir, O Aras, D Oral.   

Abstract

BACKGROUND: Observations with intravascular ultrasound demonstrated that neointimal hyperplasia is the predominant factor responsible for in-stent restenosis. Experimental data suggest that angiotensin I converting enzyme (ACE) plays a role in the thickening of neointima after balloon denudation. Insertion/deletion (I/D) polymorphism of the ACE gene is significantly associated with plasma level of ACE and subjects with D/D genotype have significantly higher plasma levels of ACE than normal.
OBJECTIVE: To investigate whether this polymorphism influences the risk of restenosis after coronary stenting.
METHODS: We genotyped 158 patients who had undergone single-vessel coronary stenting for the ACE I/D polymorphism.
RESULTS: Of the 158 patients, 56 (35%) had the D/D genotype, 71 (45%) had the I/D genotype and 31 (20%) had the I/I genotype. Prevalences of genotypes were compatible with Hardy-Weinberg equilibrium and distributions of ACE genotype among patients and 132 healthy controls from the same geographic area did not differ. At follow-up (after a median duration of 5.4 months), overall rates of angiographic restenosis and of revascularization of target lesion (RTL) were 32.3 and 22.8%, respectively. Of 51 patients with angiographic restenosis, 31 (60.8%) had focal and 20 (39.2%) had diffuse patterns of restenosis. Diffuse in-stent restenosis was significantly more prevalent among patients with D/D genotype (P = 0.016). Multiple stepwise logistic regression analysis identified ACE I/D polymorphism as the independent predictor of angiographic restenosis and RTL. Relative risk of angiographic restenosis was 6.29 [95% confidence interval (CI), 1.80-22.05, P = 0.0004] for D/D genotype and 3.88 (95% CI 1.11-13.12, P = 0.029) for I/D genotype, whereas relative risk of RTL was 7.44 (95% CI 1.60-34.58, P = 0.01) for D/D genotype and 3.88 (95% CI 0.083-18.15, P = 0.085) for I/D genotype.
CONCLUSIONS: The ACE I/D polymorphism is significantly associated with risk of angiographic and clinical restenosis after coronary stenting. Angiographic pattern of restenosis is also significantly associated with I/D polymorphism, diffuse type being more prevalent among subjects with D/D genotype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11155292     DOI: 10.1177/204748730000700602

Source DB:  PubMed          Journal:  J Cardiovasc Risk        ISSN: 1350-6277


  5 in total

1.  Angiotensin converting enzyme insertion or deletion polymorphism and coronary restenosis: meta-analysis of 16 studies.

Authors:  François Bonnici; Bernard Keavney; Rory Collins; John Danesh
Journal:  BMJ       Date:  2002-09-07

2.  Integrating genotypic data with transcriptomic and proteomic data.

Authors:  Denis C Shields; Aisling M O'Halloran
Journal:  Comp Funct Genomics       Date:  2002

3.  Genetic polymorphism of angiotensin converting enzyme and risk of coronary restenosis after percutaneous transluminal coronary angioplasties: evidence from 33 cohort studies.

Authors:  Shen Wang; Yuxiang Dai; Lingling Chen; Zhibing Dong; Yunpeng Chen; Chenguang Li; Xin Zhong; Wenhui Lin; Jifu Zhang
Journal:  PLoS One       Date:  2013-09-30       Impact factor: 3.240

4.  ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation.

Authors:  Georgios Kitsios; Elias Zintzaras
Journal:  BMC Med Genet       Date:  2009-06-04       Impact factor: 2.103

Review 5.  Influence of the angiotensin converting enzyme insertion or deletion genetic variant and coronary restenosis risk: evidence based on 11,193 subjects.

Authors:  Yang Pan; Fang Wang; Qin Qiu; Ren Ding; Baolong Zhao; Hua Zhou
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.